Hydrocodone Up-scheduling: FDA Faces Philosophical Toss-Up After Advisory Cmte.
Executive Summary
Two-thirds of FDA’s Drug Safety and Risk Management Advisory Committee say the combination products have a similar abuse profile as drugs already on Schedule II, but others note there is no guarantee drug abuse will decline with reclassification, which will adversely affect pain patients’ access to the drugs.